pharma · Hereditary Angioedema · Influenza · BCRX
Biocryst
Biocryst clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- München, DE
- Founded
- 1986
- Employees
- 6
- Programs
- 37
- Drugs
- 17
- Patents
- 72
Biocryst projects
9 ClinicalTrials.gov programs sponsored by Biocryst.
Biocryst has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BCX10013
Biocryst
Paroxysmal Nocturnal Hemoglobinuria
1 trial -
BCX17725
Biocryst
Netherton Syndrome
1 trial -
BCX4430
Biocryst
Filovirus Infections
1 trial -
BCX7353 and probes
Biocryst
Hereditary Angioedema
1 trial -
Galidesivir
Biocryst
COVID-19
1 trial -
Peldesine
Biocryst
HIV Infections
1 trial -
avoralstat
Biocryst
Diabetic Macular Edema (DME)
1 trial -
forodesine hydrochloride
Biocryst
Cancer
1 trial -
galidesivir
Biocryst
Marburg Virus Disease
1 trial
Frequently asked questions
How many clinical projects does Biocryst have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.